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Summary This paper reviews the association between periodontitis and CVD. In addition, the
potential mechanisms of any association between periodontitis and CVD as well as the effects of
periodontal treatment on CVD are herein discussed. Among the studies carried out by this group
and others on coronary artery diseases, peripheral arterial diseases, abdominal aortic aneurysm,
and Buerger’s disease, periodontopathic bacteria were frequently detected in the diseased blood
vessels, thus suggesting an association between periodontitis and CVD. The potential mechanisms
of the association between periodontitis and CVD are not fully elucidated. However, inflammation
and some autoimmune mechanisms, including molecular mimicry between the periodontopathic
bacteria and host molecules, are suggested. The effects of periodontal treatment on CVD might
thus vary among the different treatment modalities, and full-mouth mechanical debridement
might induce strong transient systemic inflammatory responses in comparison to the quadrant-
wise mechanical debridement.
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Periodontitis and cardiovascular diseases 991. Introduction
Cardiovascular disease (CVD) is a class of diseases that affect
the heart and blood vessels. Globally, CVD is the number one
cause of death and is estimated to remain so. TheWHO report
released in 2007 (Fact sheet No. 317, February 2007)
reported an estimated 17.5 million people died from CVD
in 2005, representing 30% of all global deaths.
Accumulating evidence shows that inflammation played a
central role in the pathogenesis of CVD [1,2]. Periodontitis is
an inflammatory disease caused by gram-negative period-
ontopathic bacteria which can induce the production of host
inflammatory mediators, eventually leading to the break-
down of tooth-supporting tissues [3,4]. Recent studies and
meta-analyses have demonstrated a modest but statistically
significant association between CVD and periodontitis (odds
ratios: 1.1—2.2) [5—11]. In addition, it has been suggested
that periodontitis may contribute to CVD and stroke [11,12].
Periodontal pathogens have been detected in athero-
sclerotic plaques in humans and animal models, suggesting
that periodontal infections may result in bacteremias and
enhance atherosclerotic plaque formation [13—15]. A num-
ber of inflammatory cytokines, which have been reported to
be associated with periodontitis, are also involved in ather-
othrombogenesis [16,17]. Furthermore, patients with peri-
odontal disease share many of the same risk factors as
patients with CVD including age, gender (predominantly
male), lower socioeconomic status, stress, and smoking
[18]. This suggests that periodontal disease and CVD may
share common etiological pathways and that the association
between these two diseases is plausible.
This paper reviews the association between periodontitis
and CVD with a focus on studies carried out by this group on
coronary artery diseases, peripheral arterial diseases,
abdominal aortic aneurysm, and Buerger’s disease. In addi-
tion, potential mechanisms of the association between per-
iodontitis and CVD as well as the effects of periodontal
treatment on CVD are discussed.
2. Effects of periodontitis on atherosclerosis
2.1. Coronary artery disease
Coronary arteries deliver oxygen-rich blood to the myocar-
dium. In general, there are two main coronary arteries,
which are the right coronary artery and the left coronary
artery. These arteries run on the surface of the heart and are
capable of auto-regulation tomaintain coronary blood flow at
the levels appropriate to the needs of the heart muscles.Coronary artery disease (CAD), which is also called coronary
heart disease (CHD), is the end result of the accumulation of
atheromatous plaques within the walls of the arteries.
Myocardial infarction occurs when the atheromatous
process prevents blood flow through the coronary artery.
It was previously thought that progressive luminal narrow-
ing from continued growth of smooth-muscle cells in the
plaque was the main cause of infarction. Angiographic
studies have, however, identified culprit lesions that do
not cause marked stenosis, and it is now evident that the
activation of plaque rather than stenosis precipitates in the
subsequent ischemia and infarction. Coronary spasm may
be involved to some extent, but most cases of infarction are
due to the formation of an occluding thrombus on the
surface of the plaque.
There are two major causes of coronary thrombosis:
plaque rupture and endothelial erosion. Plaque rupture,
which is detectable in 60—70% of cases, is dangerous because
it exposes pro-thrombotic material from the core of the
plaque-phospholipids, tissue factor, and platelet-adhesive
matrix molecules to the blood. Ruptures preferentially occur
where the fibrous cap is thin and partly destroyed. Activated
immune cells are abundant at these sites. They produce
numerous inflammatory molecules and proteolytic enzymes
that can weaken the cap and activated cells in the core and
transform the stable plaque into a vulnerable, unstable
structure which can rupture, induce a thrombus, and also
cause acute coronary syndrome.
Several studies have linked infections to atherosclerosis
and CAD. The conditions or infectious agents most frequently
studied are Chlamydia pneumoniae, cytomegarovirus (CMV),
herpes simplex virus (HSV), Helicobacter pylori and period-
ontitis [19].
Tooth loss may be associated with an increased risk of CAD
and stroke [20,21]. After adjusting for potential confounders,
periodontitis is associated with an increase of 25% in CAD risk
and an increased risk of up to 70% among men less than 50
years of age [22]. There does appear to be increasing evi-
dence of a relationship between dental health and CAD,
especially in men ranging from 40 to 50 years of age.
In an animal study [23], recurrent Porphyromonas gingi-
valis (P. gingivalis) bacteremia induces coronary lesions con-
sistent with atherosclerosis and accelerates coronary
atherosclerosis. Sakurai et al. [24] showed the presence of
Aggregatibacter actinomycetemcomitans (A. actinomyce-
temcomitans) to be higher in patients with acute coronary
syndrome (ACS) than in those of chronic CHD (Table 1). In
addition, ACS patients showed significantly higher serum IgG
titers against A. actinomycetemcomitans in comparison to
chronic CHD (Fig. 1). These results suggest the possibility of a
Table 1 Presence of periodontopathic bacteria in oral (saliva and/or subgingival plaque) and blood samples in coronary heart
disease patients. Patients were divided into two groups (ACS and Chronic CHD). Bacteria are detected by a polymerase chain
reaction assay.
Bacteria Oral sample Blood sample
ACS Chronic CHD ACS Chronic CHD
Aggregatibacter actinomycetemcomitans 5 (33) * 0 * 1 (7) 0
Porphyromonas gingivalis 14 (93) 10 (77) 0 0
Prevotella intermedia 10 (67) 7 (54) 0 0
Tannerella forsythia 15 (100) 12 (92) 0 0
Treponema denticola 12 (80) 11 (85) 4 (27) 2 (15)
Bacterial positive numbers (percentage). ACS: acute coronary syndrome (n = 15). Chronic CHD: chronic coronary heart disease (n = 13).
* p < 0.05.
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2.2. Peripheral vascular disease
Peripheral vascular disease (PVD) is a condition where an
obstruction of the blood flow in large peripheral arteries/
veins, often due to the formation of a thrombus, leads to
lower extremity ischemic ulceration or gangrene. The symp-
toms are intermittent claudication, rest pain, trophic
changes in the involved limb, numbness in the extremities,
and more. The most serious cases (up to 20—25% of these
patients) require amputation [25].
PVD shares a common underlying pathological change with
atherosclerosis, coronary heart diseases and stroke [26]. The
relationship between periodontitis and atherosclerosis has
been assumed since the initial observations that periodontal
pathogens were identified from atheromatous plaques
[14,27]. The association of periodontitis and PVD has only
been reported in a few studies. Mendez et al. [28] followed
up 1110 subjects over the 25 years and reported that subjects
with periodontal disease at baseline had a 2.27-fold incre-
ment in the risk of developing PVD in comparison to thosewho
had no periodontal disease at baseline (95% CI = 1.32—3.90,
p = 0.003). This relationship was significant even after the
adjustment for age, body mass index (BMI), family history ofFigure 1 Serum IgG titers of periodontopathic bacteria in
coronary heart disease patients. ACS; acute coronary syndrome
patients, chronic CHD: chronic coronary heart disease patients.heart disease, and smoking. Hung et al. [29] also conducted a
prospective cohort study (n = 342, 12-year follow up) and
reported an increased risk of PVD in subjects with periodontal
disease at baseline (RR 1.41, 95% CI = 1.12—1.77), after
adjustment for age, smoking, BMI, family history of heart
disease, hypertension, diabetes, hypercholesterolemia, and
occupation. Lu et al. [30] conducted a cross-sectional study
of 3585 subjects and performed a multiple regression ana-
lysis. Thirty-three percent or more sites of periodontal
attachment loss (PAL) > 3 mm are associated with a >2-fold
increase in the risk of PVD after adjusting for other risk
factors. Systemic markers of inflammation {C-reactive pro-
tein (CRP), white blood cell count, fibrinogen} were also
associated with PVD and PAL, suggesting that the inflamma-
tion led by oral infections may be an important pathway
linking periodontitis and PVD.
A recent case-control study evaluated the association
between periodontitis and peripheral arterial disease (PAD)
in the Japanese population (Table 2) [31]. Twenty-five PAD
patients and 32 healthy control subjects participated in the
study. The results revealed that PAD patients showed higher
titers against periodontopathic bacteria, such as P. gingivalis
and Treponema denticola, and those organisms could be
detected in atherosclerotic specimens using the polymerase
chain reaction (PCR). In addition, periodontitis increased the
risk of having PAD 5-fold (95% CI = 1.57—18.89, p = 0.007),
after adjusting for age gender, diabetes and smoking. These
aforementioned studies therefore support the hypothesis of
an association between periodontal disease and PVD. How-
ever, further studies are necessary to determine whether
periodontitis is a causal factor associated with PVD.Table 2 Association of several risk factors with peripheral
arterial disease in a logistic regression model. Independent
variables include periodontitis, smoking, age, gender, and
diabetes.
Independent variables Dependent variable: PAD p-Value
Odds ratio (95% CI)
Periodontitis 5.45 (1.57—18.89) 0.007
Smoking 0.75 (0.13—4.43) 0.754
Age 0.99 (0.94—1.05) 0.813
Gender 1.65 (0.18—15.61) 0.611
Diabetes 0.18 (0.03—1.12) 0.065
95% CI: 95% confidence interval.
Table 3 Presence of periodontopathic bacteria in an oral sample, arterial (aneurysmal) wall and mural thrombus of AAA patients.
Bacteria are detected by a polymerase chain reaction assay.
Bacteria Oral sample (n = 32) Aneurysmal wall Mural thrombus
All bacteria studied 28 (88) 24/28 (86) 14/16 (88)
Aggregatibacter actinomycetemcomitans 1 (3) 0/1 (0) 0
Campylobacter rectus 11 (34) 5/11 (45) 1/7 (14)
Porphyromonas gingivalis 26 (81) 22/26 (85) 12/15 (80)
Prevotella intermedia 13 (41) 4/13 (31) 0/7 (0)
Prevotella nigrescens 6 (19) 1/6 (17) 0/3 (0)
Tannerella forsythia 23 (72) 5/23 (22) 0/13 (0)
Treponema denticola 19 (59) 12/19 (63) 3/10 (30)
Oral samples: bacterial positive numbers (percentage). Arterial (aneurysmal) wall, Mural thrombus: bacterial positive ratio to positive
finding of those in oral samples (percentage).
Figure 2 (a) A Buerger’s disease patient. Ulceration and gang-
rene are observed in the fingers and toes. (b) A Buerger’s disease
patient. Severe recession and deep periodontal pockets are
observed in this patient.
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The abdominal aorta is the largest artery in the abdominal
cavity and supplies blood to much of this region. As part of
the aorta, it is a direct continuation of the descending aorta.
In elderly men, the infrarenal abdominal aortic diameter is
between 15 and 24 mm.
An aneurism is defined as a permanent and irreversible
localized dilation of a vessel. The definition of an abdominal
aortic aneurism (AAA) is an aorta with an infrarenal diameter
greater than 30 mm or 1.5 times the expected normal dia-
meter [32]. There are many causes of aneurismal dilation,
such as trauma, acute infection (brucellosis, salmonellosis),
chronic infection (tuberculosis), inflammatory diseases (Beh-
cet and Takayasu disease), and connective tissue disorders
(Marfan Syndrome, Ehlers-Danlos type IV). However, few
AAAs are the direct consequence of specific causes. There-
fore, most AAAs are called non-specific. Moreover, because
this disorder is invariably associated with a severe athero-
sclerotic damage of the aortic wall, it has been traditionally
regarded as a consequence of atherosclerosis.
Histologically, AAAs are characterized by the destruction
of elastin and collagen in the media and adventitia, smooth-
muscle cell loss with thinning of the medial wall, infiltration
of lymphocytes and macrophages, and neovascularization
[33]. Production and activation of various proteases and
cytokines contribute to the development of this disorder,
although the underlying mechanisms are unknown.
The pathogenesis of AAA has been suggested to involve
four mechanisms including the proteolytic degradation of
aortic wall connective tissue, inflammation and immune
responses, biomechanical wall stress, andmolecular genetics
[34].
Recent data suggest that chronic infection may play a role
in the pathogenesis of atherosclerosis, and several infectious
agents, including C. pneumoniae, oral bacteria, and herpes
virus may be involved. C. pneumoniae has also been detected
in the walls of AAA [35,36].
In addition, periodontopathic bacteria are present in AAA
and might play a role in the development of AAA. A. acti-
nomycetemcomitans is detected from both the blood and
subgingival plaque samples in endarteritis and mycotic aortic
aneurysm patients [37]. Another group also reported that A.
actinomycetemcomitans, but not bacteria of the red com-
plex [38], is detected in aortic aneurysms [39]. However,
Okuda et al. showed the presence of T. denticola in aneurysmspecimens using PCR methods and immunofluorescence
microscopy [40].
Periodontopathic bacteria are present in a high percen-
tage of specimens (86%) of diseased arteries of AAA patients,
whose oral samples (saliva or subgingival bacterial plaque)
are positive for periodontopathic bacteria [41]. P. gingivalis
and T. denticola are frequently detected among aneurismal
walls and oral samples (Table 3). These results suggest that
periodontitis might be associated with AAA.
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Buerger’s disease (also known as thromboangiitis obliterans)
is a non-atherosclerotic, segmental, inflammatory occlusive
vascular disease. It mainly affects medium-sized arteries,
veins, and the nerves of the extremities, and causes claudi-
cation or rest pain. In advanced cases, ulceration and gang-
rene are observed at the fingers and toes (Fig. 2a), often
resulting the need for amputation of the involved areas.
The diagnosis of this disease is usually made based on the
clinical symptoms. Its criteria generally include the follow-
ing: (a) history of smoking; (b) onset before the age of 50
years; (c) infrapopliteal, segmental arterial occlusions; (d)
either upper limb involvement or phlebitis migrans; and (e)
absence of exclusion of atherosclerotic risk factors other
than smoking [42]. The overall incidence in the world has
been steadily declining but it is still more prevalent in Asian
countries than in Europe or North America [43]. The patho-
logical mechanisms of Buerger’s disease are still largely
unknown, although many etiologic factors have been sug-
gested. Tobacco smoking is the only indisputable etiologic
factor of Buerger’s disease [42,43], although smoking alone
does not seem to be sufficient to cause the disease. An
autoimmune response may also implicated in the onset of
Buerger’s disease, and several studies have reported etiolo-
gic factors of the disease, including disorders of T-cell and B-
cell mediated humoral immunity [44,45], cellular sensitivity
to collagen [46,47], and HLA patterns [48]. However, these
theories cannot account for the formation of phlebitis
migrans, a principal characteristic of Buerger’s disease, or
explain why this disease affects both arteries and veins
simultaneously and, occasionally, nerves. The various fea-
tures of Buerger’s disease might be better explained by
considering the disease as a systemic reaction to bacterial
infection or to an antigen originating from bacteria rather
than as an immunological disorder.
Allen and Brown note the possibility that oral infection
serves as a contributory factor of the inflammation of Buer-
ger’s disease [49], while no previous study has reported that
specific pathogens were identified in the vessel lesion. Per-
iodontitis as a chronic bacterial infectious disease was
involved in Buerger’s disease, and thus the association
between periodontitis and pathogenic bacteria was investi-
gated [50,51]. These are the first studies to report a relation-
ship between Buerger’s disease and periodontitis. Buerger’s
disease patients exhibited poor periodontal conditions
(Fig. 2b). Periodontopathic bacteria such as P. gingivalis
and T. denticola were detected in both saliva and arterial
specimens of the Buerger’s disease patients by a PCR analysis,
while none of the control arterial samples without Buerger’s
disease was positive for these bacteria. Furthermore, Buer-
ger’s disease patients showed higher IgG titers against per-
iodontopathic bacteria, thus indicating that these bacteria
might trigger immune responses and play a significant role in
the pathogenesis of Buerger’s disease.
3. Potential mechanisms of the association
between periodontitis and CVD
Some studies have suggested that potential links between
periodontitis and CVD include direct effects from bacteriaand indirect effects through host inflammatory responses as
well as autoimmune responses. Since the DNA of P. gingivalis
has been detected in atherosclerotic plaques [14,52] and
periodontal infections can result in bacteremias and endo-
toxemias in the patients [53—55], systemic effects on the
cardiovascular system through these exposures seem biolo-
gically reasonable. Three potential mechanisms of the asso-
ciation between periodontitis and CVD include:
 direct bacterial effects on platelets and host cells,
 systemically or locally induced inflammatory mediators,
 autoimmune responses.
Platelets play a critical role in hemostasis and thrombosis.
In vitro studies on the interaction of platelets with two
bacteria found in the oral cavity, Staphylococcus aureus
and Streptococcus sanguis, have shown that the bacteria
can induce platelet aggregation [56—58]. Recent studies
have demonstrated that P. gingivalis can also activate plate-
lets, induce platelet aggregation and increase protease
activity [59—61]. An ultrastructural study of P. gingivalis-
induced platelet aggregation was conducted using electron
microscopy [62]. A sharp and rapid increase of small-sized
platelet aggregates was observed immediately after the
addition of P. gingivalis to human platelet rich plasma
(PRP), followed by the formation of medium- and large-sized
aggregates in 2—3 min. Furthermore, P. gingivalis was mostly
present between the adherent platelets and some were
internalized in platelet vacuoles by phagocytosis. Based on
these findings, a similar pathologic process can be extrapo-
lated to occur in the human cardiovascular system.
The direct effects of periodontopathic bacteria on host
cells may contribute to the link between periodontitis and
CVD. Invasion and/or uptake of bacteria in endothelial cells
and monocytes have been reported [63]. Several groups of
investigators have identified periodontal pathogens including
P. gingivalis and A. actinomycetemcomitans in cardiovascular
specimens [13,14,52,63]. In addition, a previous study
showed that P. gingivalis can invade aortic and heart
endothelial cells via fimbriae [64].When humanmacrophages
are incubated with low density lipoprotein and P. gingivalis,
the bacteria are internalized in macrophages and signifi-
cantly increase foam cell formation, the hallmark of early
atherogenesis [65]. The P. gingivalis LPS fraction markedly
upregulate ICAM-1 and VCAM-1 in human umbilical vein
endothelial cells (HUVECs) and facilitate mononuclear cell
adhesion to HUVECs [66]. These results suggest that a period-
ontal infection by P. gingivalis may promote monocyte
recruitment to the vascular endothelium and contribute to
atherogenesis.
Periodontitis and CVD potentially share similar hallmarks
of inflammation. Several lines of evidence indicate that
tissue destruction in periodontitis is more related to host
inflammatory responses than the detrimental direct effects
of the periodontopathic bacteria themselves. Atherosclerosis
is currently viewed as a progressive inflammatory process
rather than as simply an accumulation of lipids. Various
inflammatory signals and markers including high sensitivity
CRP (hsCRP), fibrinogen, and various inflammatory cytokines
{i.e. interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-
alpha}, are involved in atherothrombogenesis [17,67].
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cardiovascular events [68]. Inflammation, as reflected in the
concentration of hsCRP, precedes the onset of cardiovascular
events, confirming that atherothrombosis is, at least in part,
an inflammatory disorder. It should be noted that the inflam-
matory mediators involved in CVD have also been reported to
be associated with periodontitis. Periodontopathic bacteria
can gain access to the blood circulation and have been
detected in human cardiovascular specimens [63,69]. There-
fore, the potential mechanism for linkage between period-
ontitis and CVD is inflammation, in which periodontopathic
bacteria induce host cells to produce inflammatory cytokines
either systematically or locally and these cytokines in turn
play important roles in the development or progression of
CVD.
Circulating immune cells as well as serum inflammatory
mediators are activated in periodontitis patients. It has been
proposed that a systemic hyper-inflammatory monocyte
state might place a patient at risk for both periodontitis
and atherosclerosis [21]. The findings that CD14+CD16+mono-
cytes and CD45RA+ monocytes increase in chronic and aggres-
sive periodontitis, respectively, suggest that monocytes in
periodontitis patients have activated surface phenotypes in
comparison to the periodontally healthy subjects. Further-
more, CD14+CD16+ monocytes produce more IL-6 than CD16-
monocytes in response to LPS from Escherichia coli and A.
actinomycetmcomitans, thus suggesting that CD14+CD16+
monocytes represent the hyper-inflammatory phenotype
[70].
In addition to the effects of inflammatory responses on
CVD, molecular mimicry has been suggested as a potential
mechanism of the association between infection and CVD.
The term ‘‘molecular mimicry’’ was coined by R. Damian in
1964, who was the first to suggest that antigenic determi-
nants of microorganisms may resemble antigenic determi-
nants of their host. Damian suggested that this similarity
serves as a defense mechanism of a microorganism against
the host’s immune system and prevents the development of
an immune response to the microorganism, thereby protect-
ing it from the host defense. Years later, the term ‘‘molecular
mimicry’’ was attributed a different meaning namely, anti-
genic determinants of microorganisms might elicit an auto-
immune response that harms the host [71]. An infection with
H. pylori induces anti-heat shock protein (HSP) antibody and
HSP-specific T lymphocytes by molecular mimicry. The pre-
sence of anti-HSP60 antibodies and HSP60-specific T lympho-
cytes may increase the risk of atherosclerosis [72].Table 4 Molecular mimicry between beta-2-glycoprotein I (b2GPI
homologous sequences with TLRVYK on b2GPI were found in seve
mitans, P. gingivalis and T. denticola.
Antigens
b2 Glycoprotein I
Tetanus toxoid
P. gingivalis gingipain
T. denticola phosphoglycerate kinase
A. actinomycetemcomitans leukotoxin cAutoimmune responses caused by the molecular mimicry
between periodontopathic bacteria and HSP have also been
reported [73,74]. Yamazaki et al. [75] showed that antibody
levels to human HSP60 and P. gingivalis HSP60 (GroEL) are
highest in patients with atherosclerosis, followed by period-
ontitis patients and healthy subjects. Patients with athero-
sclerosis have HSP60-reactive as well as GroEL-reactive T
cells and that atherosclerotic lesions are infiltrated with
HSP60-reactive Tcells. These studies suggest the mechanism
of molecular mimicry between HSP and periodontopathic
bacteria to be a possible link between periodontitis and
atherosclerosis.
In addition to CVD, periodontitis is also associated with an
adverse pregnancy outcome [12,76]. An autoimmune dis-
ease, anti-phospholipid-antibody syndrome is associated
with both CVD and adverse pregnancy outcome. The major
clinical symptoms of anti-phospholipid syndrome are recur-
rent thrombosis, fetal loss, and premature atherosclerosis
[77]. The anti-phospholipid antibody has pro-thrombotic
activity, and elevated level of the antibody is a hallmark
of anti-phospholipid syndrome. Among the anti-phospholipid
antibodies, beta-2-glycoprotein-I-dependent anti-cardioli-
pin (anti-CL) antibody, and lupus anticoagulant (LA) are
major groups of antibodies increased in anti-phospholipid
syndrome patients. Different clinical and experimental stu-
dies of the beta-2-glycoprotein-I molecule have linked an
infection to the development of anti-phospholipid syndrome
[71]. Based on the remarkable similarity between the symp-
toms of anti-phospholipid syndrome and the reported sys-
temic sequelae of periodontitis, as well as the likely
infectious origin of anti-CL antibodies, Schenkein et al.
[78] hypothesized that periodontal infection might induce
production of anti-phospholipid antibodies. They reported
that the prevalence of patients with chronic periodontitis
and generalized aggressive periodontitis positive for anti-CL
was greater than that in healthy controls.
Blank et al. identified a hexapeptide (TLRVYK) sequence in
beta-2-glycoprotein-I which is recognized by a monoclonal
anti beta-2-glycoprotein-I antibody, and the monoclonal
antibody which is elicited in the experimental anti-phospho-
lipid syndrome in mice. Various microbial pathogens, includ-
ing Haemophilus influenzae, Neisseria gonorrheae or tetanus
toxoid, bear a homologous sequence to TLRVYK peptides.
Immunization of mice with these microbial pathogens induce
anti-phospholipid syndrome [79].
The homologous sequence in periodontopathic bacteria
was searched in the Swiss plot database, and a sequence) and bacterial peptides. According to the Swiss plot database,
ral periodontopathic bacteria, including A. actinomycetemco-
Peptide sequence
152—157 CATLRVYKGG
956—958 SFWLRVKVSA
1224—1226 DRILRVGYNA
1245—1249 AVKLRDLKTY
181—185 TKTLRIYTEI
320—329 PKTLALYKEI
120—123 FRSIRVYKGS
104 Y. Izumi et al.homologous to TLRVYK was thus revealed in the to reside in
leucotoxin c of A. actinomycetemcomitans (SIRVYK), phos-
phoglycerate kinase of T. denticola (TLALYK) and P. gingivalis
gingipain (TLRIYT; Table 4). The effects of A. actinomyce-
temcomitans infection on the antibody response against
SIRVYK peptides were examined in patients with periodonti-
tis. The level of anti-SIRVYK antibodies was significantly
higher in chronic periodontitis patients who were A. actino-
mycetemcomitans-positive than in negative patients. The
anti-TLRVYK antibody levels significantly correlated with
anti-SIRVYK IgG antibody levels. The results suggested that
A. actinomycetemcomitans infection might elicit anti-SIRVYK
IgG antibodies andmodify the anti-TLRVYK antibody response
in patients with periodontitis by molecular mimicry with
beta2GPI. The molecular mimicry between periodontopathic
bacteria and beta2GPI might be a relevant mechanism that
enhances the risk of CVD in periodontitis patients [80].
4. Effects of periodontal treatment on
cardiovascular diseases
An elevation of CRP is currently regarded as a biomarker of
systemic inflammation and increased risk for CVD [81]. hsCRP
has been shown to be the strongest biomarker for predicting
cardiovascular events [68]. A recent meta-analysis of 10
cross-sectional studies showed that CRP in periodontitis
patients is elevated in comparison to controls without period-
ontitis [82]. In addition, the presence of P. gingivalis in
periodontitis patients is associated with increased CRP
levels, suggesting that the elimination of the periodonto-
pathic bacteria might reduce the serum CRP levels [83].
Available data from pilot studies suggests that periodontal
intervention can improve surrogate serum biomarkers and
vascular responses associated with CVD. Results from ameta-
analysis indicate that the periodontal treatment could lowerFigure 3 Fluctuations of serum IL-6 following quadrant or full-m
patients were collected before, immediately after and 1 month after
*Higher IL-6 levels were associated with a 2-fold greater risk of death (
to the lowest quartile of (<1.9)) (Ref. [88]). **The unstable coronary a
ml had increased mortality (Ref. [89]).the levels of CRP after therapy [82]. Furthermore, a recent
multi-centered randomized control study (the Periodontitis
and Vascular Events; PAVE) showed that periodontal treat-
ment can reduce the CRP levels from high to moderate levels
in non-obese periodontitis patients [84]. However, race/
ethnicity is known to affect CRP, and CRP levels in Asian
adults are lower than in Westerners [85]. As the distribution
of serum CRP level is skewed toward lower levels in the
Japanese population, it is difficult to detect significant
changes of serum CRP after periodontal therapy in Japanese
population [86,87].
Other biomarkers significantly associated with the risk of
cardiovascular events are serum amyloid A, sICAM-1, IL-6,
homocysteine, total cholesterol, low density lipoprotein
(LDL) cholesterol [16]. Among them, the IL-6 plasma levels
in the upper quartile of the considered normal range are
independently predictive of an increased risk of premature
death or future myocardial infarction, even after accounting
for the CRP level in large prospective studies of healthy
populations [66,88]. IL-6 is also a marker for identifying
patients with unstable coronary artery disease independent
of other risk indicators [89]. The patients with plasma levels
of IL-6 higher than 5 pg/ml have increased mortality. The
plasma IL-6 levels are also different among ethnic groups.
The mean levels of IL-6 in Chinese (1.1 pg/ml) are lower than
those in African American (1.7 pg/ml), Hispanic (1.7 pg/ml)
and non-Hispanic white (1.5 pg/ml). After adjustment for
age, gender, ethnicity, smoking, diabetes, hypertension,
dyslipidemia and BMI, 1-SD increments in the IL-6 levels
are associated with the increased odds for peripheral arterial
disease [90]. These results suggest that IL-6 might also be
used as a surrogate marker to examine the effect of period-
ontitis on cardiovascular diseases.
Although the data from intervention studies have sug-
gested that the values of serummarkers of inflammation may
significantly decrease after periodontal treatment, theyouth mechanical debridement. Sera from chronic periodontitis
mechanical debridement, and serum IL-6 was examined by ELISA.
relative risk for the highest quartile (>3.19 pg/ml) in comparison
rtery disease patients with plasma levels of IL-6 higher than 5 pg/
Figure 4 Fluctuations of serum CRP following quadrant or full-mouth mechanical debridement. Sera from chronic periodontitis
patients were collected before, immediately after and 1 month after mechanical debridement, and serum CRP was examined using a
highly sensitive CRP test.
Periodontitis and cardiovascular diseases 105were increased immediately after periodontal therapy [91].
Whether such increases in values suggest serious adverse
events remains unknown. Full-mouth disinfection was intro-
duced as a method to suppress periodontopathic bacteria by
completing the scaling and root planning (SRP) in a short
period of time (within 24 h). Full-mouth disinfection is based
on the hypothesis that conventional quadrant-wise SRP might
cause re-infection of the treated sites from the un-treated
quadrants. There are clinical benefits of single-visit full-
mouth mechanical debridement (FMD) over quadrant-wise
mechanical debridement (QMD) [92]. Furthermore, the
effects of the treatments on the levels of serum IL-6 and
CRP were examined [87]. A transient increase of serum IL-6 is
observed in both treatment groups, and it is higher in the FMD
group than in the QMD group (Fig. 3). Themean CRP levels are
increased in the FMD group and decreased in the QMD group
at 1month after treatment, although the difference between
the two groups is not statistically significant (Fig. 4). These
results suggest a potential effect of periodontal treatment on
systemic inflammation.
Presently, the available evidence demonstrating the ben-
eficial effects of periodontal intervention directly on CVD is
still limited. A recent randomized controlled trial (RCT)
revealed that intensive periodontal therapy results in an
improvement in endothelial function after 6 months [93].
However, further properly powered longitudinal case control
studies and intervention RCT are still needed. To design and
carry out such studies could be problematic due to financial
and ethical concerns. Both periodontitis and CVD are chronic
in nature, and those chronic inflammatory conditions may
develop over a number of years before the diseases are
diagnosed. It is conceivable that the contributory effects
of periodontitis on cardiovascular disease take place over a
similarly extended period of time. Therefore, it may be
difficult to reduce future cardiovascular events or symptoms
by simply treating periodontal disease at the time when one
or both diseases are diagnosed since the damage might have
already occurred over the decades and become largely irre-
versible. Nevertheless, clinicians and patients should recog-nize the consistent association between periodontal diseases
and CVD along with the potential preventive benefits of
appropriate periodontal intervention. Further investigations
are warranted to determine the benefits of periodontal
therapy on the development and progression of CVD.
5. Conclusion
Based on the findings of studies carried out by this group and
others on coronary artery diseases, peripheral arterial dis-
eases, abdominal aortic aneurysm, and Buerger’s disease, an
association between periodontitis and CVD is therefore
strongly suggested. The potential mechanisms of the asso-
ciation between periodontitis and CVD are not fully under-
stood. However, inflammation and autoimmune mechanisms,
including molecular mimicry between periodontopathic bac-
teria and host molecules, are suggested to be the relevant
mechanisms which link periodontitis to CVD. The effects of
periodontal treatment on CVD might be different among the
different treatment modalities. Further studies should there-
fore be conducted to elucidate the effects of periodontal
therapy on the prevention of CVD.
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